Entrectinib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Entrectinib |
| DrugBank ID | DB11986 |
| Brand Names (EU) | Rozlytrek |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.58% |
Approved Indication (EMA)
Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options. Rozlytrek as monotherapy is indicated for the treatment of adult patients w
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | multiple endocrine neoplasia | 98.58% | DL |
| 2 | amenorrhea (disease) | 98.37% | DL |
| 3 | thrombocytopenia | 98.11% | DL |
| 4 | cytomegalovirus infection | 97.97% | DL |
| 5 | pulmonary hypertension | 97.87% | DL |
| 6 | marcothrombocytopenia with mitral valve insufficiency | 97.80% | DL |
| 7 | hereditary thrombocytopenia with normal platelets | 97.79% | DL |
| 8 | female breast carcinoma | 97.76% | DL |
| 9 | transient neonatal thrombocytopenia | 97.76% | DL |
| 10 | infectious bovine rhinotracheitis | 97.74% | DL |
| 11 | malignant catarrh | 97.74% | DL |
| 12 | myeloid leukemia | 97.69% | DL |
| 13 | dense granule disease | 97.66% | DL |
| 14 | kyphoscoliotic heart disease | 97.51% | DL |
| 15 | HER2 positive breast carcinoma | 97.36% | DL |
| 16 | thrombotic disease | 97.00% | DL |
| 17 | hyperthyroidism | 97.00% | DL |
| 18 | collagenopathy | 96.64% | DL |
| 19 | lymphocytic hypereosinophilic syndrome | 96.56% | DL |
| 20 | platelet storage pool deficiency | 96.54% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.